From Genes to Health – Challenges and Opportunities by Muhammad Ramzan Manwar Hussain et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PEDIATRICS
MINI REVIEW ARTICLE
published: 03 March 2014
doi: 10.3389/fped.2014.00012
From genes to health – challenges and opportunities
Muhammad Ramzan Manwar Hussain1*, Asifullah Khan2 and Hussein Sheikh Ali Mohamoud 1*
1 Princess Al-Jawhara Al-Brahim Center of Excellence in Research of Hereditary Diseases (PACER-HD), Department of Genetic Medicine, King Abdulaziz University,
Jeddah, Saudi Arabia
2 Department of Biochemistry, AbdulWali Khan University, Mardan, Pakistan
Edited by:
George P. Patrinos, University of
Patras, Greece
Reviewed by:
Alessio Squassina, University of
Cagliari, Italy
Mirko Manchia, Dalhousie University,
Canada
Khalid Moghem Al-Harbi, Taibah
University, Saudi Arabia
*Correspondence:
Muhammad Ramzan Manwar
Hussain and Hussein Sheikh Ali
Mohamoud, Princess Al-Jawhara
Al-Brahim Center of Excellence in
Research of Hereditary Diseases
(PACER-HD), Department of Genetic
Medicine, King Abdulaziz University,
Abdullah Sulayman Street, Jeddah
22254, Saudi Arabia
e-mail: geniouschemist26@
gmail.com; mrmhussain@kau.edu.sa
In genome science, the advancement in high-throughput sequencing technologies and
bioinformatics analysis is facilitating the better understanding of Mendelian and complex
trait inheritance. Charting the genetic basis of complex diseases – including pediatric can-
cer, and interpreting huge amount of next-generation sequencing data are among the
major technical challenges to be overcome in order to understand the molecular basis
of various diseases and genetic disorders. In this review, we provide insights into some
major challenges currently hindering a better understanding of Mendelian and complex
trait inheritance, and thus impeding medical benefits to patients.
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GENOMICS AND MENDELIAN PUZZLES
Single-gene mutations in the form of rare clinical phenotypes and
Mendelian disorders are being identified in every age and sex
group of the human population (1). After characterizing genes
and mutations for over 2500 Mendelian disorders in the human
genome project (HGP) (2), tremendous progress has been made
in developing fast strategies for entire human exome sequencing
(3). However, in order to discover the full spectrum of Mendelian
phenotypic variations, it is necessary to inspect gene-regulatory
sequences more closely. Mutations in either of two different but
adjacent genes with cis-regulatory module (i.e., sharing a common
regulatory region) in Joubert syndrome provide a good example
of how human genetics is expanding from the single-gene concept
to a more genomic outlook (4). In the human genome sequence,
the widespread conservation of non-coding DNA carries a variety
of regulatory elements that either enhance, suppress, or insulate
the transcription of genes (5).
In Mendelian genetics, two puzzles have been recognized as a
result of mutation analyses of single-gene defects. The first mys-
tery is that not all individuals with a particular disorder have
recognizable coding mutations; the second is that not all indi-
viduals with the same disease-causing mutation, even within a
family, suffer from the disease, and some of them may be com-
pletely unaffected (4). The second puzzle is considered as being
the more challenging, due to variation in disease penetrance and
expressivity. In order to understand disease-phenotypes, scien-
tists are trying to relate phenotypic variations, observed as a
result of penetrance and expressivity, with molecular level changes
(6–8). For example, why is one member of a family with muta-
tion in Rb1 gene affected with retinoblastoma (OMIM: 180200)
and not the other – although both carry the same mutation (9,
10). Similarly, why does the disease severity for neurofibromato-
sis (OMIM: 162200) differ significantly between two members
of a family harboring the same mutation in the neurofibromin
(NF1) gene (11). After studying this persistent challenge, scien-
tists have concluded that various contributory factors, includ-
ing modifier genes (12), environmental factors (4), allelic vari-
ations, and complex genetic and environmental interactions, all
play a role in regulating variable disease-phenotypes in humans.
However, a full and accurate understanding of these factors
in order to resolve such Mendelian puzzles is still a work in
progress.
In addition to monogenic disorders (which does not mean
monocausal), understanding the genetic basis of complex modes
of inheritance relating to diseases of digenic, trigenic, and even
more complex traits, is another challenge in genome science. In
analyzing complex modes of inheritance, genome-wide associa-
tion study (GWAS) strategies have not lived up to earlier expecta-
tions for the discovery of complex traits, due to the erroneous
assumption that common disorders are regulated by common
genetic risk factors (13). The systematic elucidation of mono-
genic disorders by means of genomic research is an important tool
for characterizing the function of genes and of course the whole
genetic architecture (13, 14). The scientific community believes
that whole-genome sequencing may resolve the dilemma of more
complex inheritance in the near future (3).
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CLINICAL BENEFITS AND GENETIC DIVERSITY – A MAJOR
CHALLENGE
Population genetic studies are important for understanding the
distribution of genetic variability among populations, inferring
their demographic histories and their adaptation to natural selec-
tion and genes flow, associated with human diseases and health
(15). Moreover, in medical research, genetic diversity has become
both a challenge and an opportunity for understanding specific
genetic factors, facilitating improvements in diagnosis, risk fac-
tor identification, differential treatment, and eventually, in more
effective cures and the prevention of human disease (16). The
achievement of entire human genome sequence information dur-
ing the HGP and its combination with the international HapMap
project has characterized approximately 10 million common vari-
ants in different world populations (17). To develop a greater
understanding of low-frequency and rare human genomic vari-
ations, a project dealing with the sequencing of 1000+ indi-
viduals from different population has already been conducted
(2). The knowledge of the involvement of genetic and epige-
netic factors in disease and the interpretation of associated cel-
lular and biological processes, are the principal tools to trans-
late genomic discoveries into novel therapeutic approaches in
medical practice. However, there are still considerable barriers
to overcome, and the anticipated improvements in the effec-
tiveness of health care may not be achievable until sometime
in the next decade (Najib Al-Khaja, Centre for Arab Genomic
Studies) (13).
Today, clinicians are faced with the difficulty of choosing
between disease-targeted sequencing tests and high-throughput
sequencing (genome and exome sequencing) approaches (18).
Within the scientific community, people still need a deeper under-
standing of human genome biology and bioinformatics tools to
analyze huge datasets to interpret the genetic variants in order
to approach differential diseases diagnosis and therapies (19,
20). However, in the future, the cost-effective personal genome
sequencing of an individual, and the interpretation of sequence
variation into biologically meaningful conclusions, is likely to
become a standard component of health care.
PEDIATRIC CANCER GENOME PROJECT
In developed countries, cytotoxic chemotherapy and radiothera-
pies have raised the overall success rate in the treatment of pediatric
cancer to 80%. However, a great reduction in life quality due to
major side-effects of therapies is limiting the success of therapy
(21–23). During early age organ development and maturation,
the spectrum of mutations causing malignant transformations
results in notable differences in the spectrum of cancers between
children and adults (24, 25). Understanding the genetic abnor-
malities underlying adult and pediatric cancers is an essential
step in developing novel drug therapies for cancers, and espe-
cially so for pediatric cancers. In 2010, an effort was compiled in
the form of the Pediatric Cancer Genome Project (PCGP), estab-
lished by St. Jude Children’s Research Hospital and the Genome
Institute at Washington University, and with the aim of explor-
ing both inter- and intra-chromosomal rearrangements, and the
mechanisms of mutagenesis. The PCGP should not only provide
a unique understanding of modified signaling pathways in cancer
but also indicate improved ways of achieving vital therapeutic
targets, especially for children (26).
The presence of structural variations in repetitive DNA
sequences, heterogeneity within tumor samples, and mutations
affecting the regulatory regions of genes are the main foci of
PCGP’s aim of better understanding the complications of genome
data interpretation. The human reference genome still carries gaps
and there is an incomplete picture of the full set of genome vari-
ations in human population groups (26). Hence, in a wide range
of projects, paired-end sequencing technology is still struggling
to create a full picture of structural variations in repetitive DNA
sequences (26, 27).
The striking degree of diversity in human tumor samples
has resulted in the initiation of a number of different cancer
projects aimed at developing the accurate estimation of can-
cer cells intermixing with normal support and immune cells
(26). Finally, mutation-profiling studies (frequency and func-
tional consequences using large numbers of samples) in the large
conserved DNA regions need precise analytical methods to inves-
tigate mRNAs, non-coding RNAs, and epigenetic data on CpG
methylation.
CHALLENGES TO NEXT-GENERATION SEQUENCING
ANALYSIS
Over the last decade, numerous advances in the fields of structural
and functional genomics have taken place (20). High-throughput
next-generation technologies are being widely used to explore such
fields, aiming to complete the diagnostic odyssey in search of cost-
effective techniques (18). The scale and efficiency of sequencing
is being harnessed by researchers to address specific clinical prob-
lems, and to more fully understand the complexities of human
biology and the place of epigenetic mechanisms (16).
After microarray technology, next-generation sequencing
(NGS) technology has made the problem of data analysis more
challenging by generating substantial data in the form of whole-
genome sequencing, exome sequencing, transcriptome analysis,
expression profile chromatin immunoprecipitation-based (ChIP)
sequencing, and methylome (epigenetics) (18). In NGS, genome
level alignment and short reads assembling of huge data volumes
carry technical challenges to get accurate identification of variants
base calling in the form of SNPs, SNVs, and indels, especially at
the repetitive loci of human genome (28). IGV and SAM tools
are being used to resolve the erroneous alignment problem of
multi-reads, manually. However, this is not usually a feasible strat-
egy for very large NGS datasets. SNP calling using GATK, MAQ,
SAMtools, SOAPsnp, or VarScan programs is the next approach in
computational pipeline after reads mapping. The accurate de novo
assembly of short reads, at repetitive loci, as delivered by most NGS
technologies, is challenging. In addition to creating gaps, complex
and misassembled rearrangements could be resulting from the
erroneous collapse of repeats on one another. Consequently, the
accurate and scalable assessment of structural variations solely by
NGS platform is still problematic. (20). Despite these challenges,
two class of de novo assemblers, i.e., overlap-based assemblers and
de Bruijn graph assemblers, have been developed to tackle this
problem (28, 29). After collection and data interpretation, the
next challenge is in accessing and sharing large scale data to the
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researchers for further comparative genome analysis. However, in
disease genomics, the development of cutting-edge algorithms for
quick data analysis of NGS datasets using table computers may be
helpful to bring potential medical benefits to patients.
CONCLUSION
Recent progress in acquiring complete genome sequence informa-
tion is leading toward a personalized medicine tradition. Although
whole genome and exome sequencing strategies are contribut-
ing to anticipate clinically significant variants, these are still in
infancy. The accurate understanding of factors influencing rare
Mendelian and common genetic traits, and the precise handling
of high-throughput next-generation data, are the most signifi-
cant technical challenges still impeding the medical benefits to
patients. However, the cost-effective application of NGS tech-
nologies – quick, secure, accurate analysis of large scale NGS
data – for identification of common and rare genetic variants
across the human populations and diseased individuals together
with advancement in the fields of proteomics and metabolomics
will provide a way of knowledge transfer from scientific literature
toward clinical practices.
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